文献速递妇科

晚期卵巢癌患者按治疗类型分组的结局与长期随访:纪念斯隆凯特琳癌症中心Team Ovary研究

Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
PubMed 文献 · Gynecol Oncol · 2022-12-22

该研究纳入2015年1月1日至12月31日在一家三级癌症中心接受初始治疗的153例新诊断III-IV期卵巢癌患者,回顾性分析按治疗类型分组的长期结局,中位随访65.8个月。初次肿瘤细胞减灭术组、中间性肿瘤细胞减灭术组和未手术化疗组的中位无进展生存期分别为26.2、13.5和4.2个月(P < .001),全队列5年总生存率为53.2%(95% CI: 44.7%-61%)。

要点

  • 153例患者中58%接受初次肿瘤细胞减灭术,33%接受新辅助化疗后中间性肿瘤细胞减灭术,9%仅化疗未手术。
  • 三组中位无进展生存期分别为26.2、13.5和4.2个月(P < .001)。
  • 全队列5年总生存率为53.2%(95% CI: 44.7%-61%),三组分别为71.5%、35.2%和7.9%。

核心结论

  • 本文描述的晚期卵巢癌患者纵向治疗模式及结局可用于患者咨询、长期规划及未来比较研究。

研究设计与样本

  • 回顾性分析2015年1月1日至12月31日在一家三级癌症中心接受初始治疗的153例新诊断III-IV期卵巢癌患者,复习电子病历获取临床病理、治疗和生存特征。

主要发现

  • 153例患者中88例(58%)为III期,65例(42%)为IV期;中位随访65.8个月(范围3.6-75.3)。
  • 89例(58%)接受初次肿瘤细胞减灭术(PDS),50例(33%)接受新辅助化疗后中间性肿瘤细胞减灭术(IDS),14例(9%)仅接受化疗未手术(NSx)。
  • PDS、IDS和NSx组的中位至首次复发无进展生存期分别为26.2个月(范围20.1-36.2)、13.5个月(范围12-15.1)和4.2个月(范围1.1-5.8)(P < .001)。
  • 首次复发/进展时,80例(72.7%)接受化疗,28例(25.5%)接受二次肿瘤细胞减灭术(CRS)后化疗,2例(1.8%)未治疗;7例(4.6%)因恶性肠梗阻接受姑息性手术;总体62.7%接受1-3线化疗。
  • 全队列5年总生存率为53.2%(95% CI: 44.7%-61%);PDS组为71.5%(95% CI: 60.2%-80%),IDS组为35.2%(95% CI: 22.2-48.5%),NSx组为7.9%(95% CI: 0.5%-29.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess long-term outcomes of patients with advanced-stage ovarian cancer by treatment type. METHODS: Patients with newly diagnosed stage III-IV ovarian cancer who underwent primary treatment at our tertiary cancer center from 01/01/2015-12/31/2015 were included. We reviewed electronic medical records for clinicopathological, treatment, and survival characteristics. RESULTS: Of 153 patients, 88 (58%) had stage III and 65 (42%) stage IV disease. Median follow-up was 65.8 months (range, 3.6-75.3). Eighty-nine patients (58%) underwent primary debulking surgery (PDS), 50 (33%) received neoadjuvant chemotherapy followed by interval debulking surgery (IDS), and 14 (9%) received chemotherapy alone, without surgery (NSx). Median PFS to first recurrence was 26.2 months (range, 20.1-36.2), 13.5 months (range, 12-15.1), and 4.2 months (range, 1.1-5.8) in the PDS, IDS, and NSx groups, respectively (P < .001). At first recurrence/progression, 80 patients (72.7%) were treated with chemotherapy, 28 (25.5%) underwent secondary cytoreductive surgery (CRS) followed by chemotherapy, and 2 (1.8%) received no treatment. Seven patients (4.6%) underwent palliative surgery for malignant bowel obstruction. Overall, 62.7% received 1-3 lines of chemotherapy. The 5-year OS rates were 53.2% (95% CI: 44.7%-61%) for the entire cohort, 71.5% (95% CI: 60.2%-80%) for the PDS group, 35.2% (95% CI: 22.2-48.5%) for the IDS group, and 7.9% (95% CI: 0.5%-29.9%) for the NSx group. CONCLUSION: The longitudinal treatment modalities and outcomes of patients with advanced ovarian cancer described here can be useful for patient counseling, long-term planning, and future comparison studies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ehmann S, Shay K, Zhou Q, et al. Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2022. PMID: 36565685. doi:10.1016/j.ygyno.2022.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。